ArticleMolecular cancer research : MCR2019
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 60 citations in OpenAlex.
- Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.Breast cancer research and treatment · 2025Trial
- Decoding PARP roles in breast cancer therapy resistance.Molecular biology reports · 2026Review
- Zoledronic Acid Inhibits the Growth of ER-Positive Breast Cancer Cells by Inducing Ferroptosis.Biomolecules & therapeutics · 2026Article
- Review
- RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer.Journal of translational medicine · 2026Article
- The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Frontiers in immunology · 2026Review
- Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer.Cellular & molecular biology letters · 2025Review
- HER2-Positive Breast Cancer Treatment and Resistance.Advances in experimental medicine and biology · 2025Review
- MBC PathNet: integration and visualization of networks connecting functionally related pathways predicted from transcriptomic and proteomic datasets.Bioinformatics advances · 2025Article
- Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.Cancer research · 2024Article
- Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.Annals of translational medicine · 2024Article
- Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.Journal of cancer research and clinical oncology · 2024Article
- Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.Molecules (Basel, Switzerland) · 2023Review
- Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- YAP/TAZ: Molecular pathway and disease therapy.MedComm · 2023Review
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer.Cancer communications (London, England) · 2023Article
- The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.British journal of cancer · 2023Review
- RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence.Oncogene · 2023Article
- ABCA9, an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP-2 signaling.Cancer science · 2023Article
- MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer.Cell death & disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 2 countries.
Vidyalakshmi SethunathLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Huizhong HuLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Carmine De AngelisLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Jamunarani VeeraraghavanLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Lanfang QinLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Nicholas WangDepartment of Biomedical Engineering and OHSU Center for Spatial Systems Biomedicine, Portland, Oregon.ORCID 0000-0003-1957-7160
Lukas M SimonInstitute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany.
Tao WangLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-1957-7160
Xiaoyong FuLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Agostina NardoneLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Resel PereiraLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Sarmistha NandaLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-0843-4271
Anna TsimelzonLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Chad ShawDepartment of Molecular & Human Genetics, Baylor College of Medicine, Houston, Texas.
Gary C ChamnessLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Laura M HeiserDepartment of Biomedical Engineering and OHSU Center for Spatial Systems Biomedicine, Portland, Oregon.ORCID 0000-0003-3330-0950
Susan G HilsenbeckLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-7962-673X
Shixia HuangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Mothaffar F RimawiLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Joe W GrayDepartment of Biomedical Engineering and OHSU Center for Spatial Systems Biomedicine, Portland, Oregon.
C Kent OsborneLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Rachel SchiffLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. rschiff@bcm.edu.
Baylor College of Medicine · USOregon Health & Science University · USMemorial Sloan Kettering Cancer Center · USBaylor Genetics · USHelmholtz Zentrum München · DEJames S. McDonnell Foundation · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Xiang Zhang · 2014 to 2026
$24.5MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA058183NCI NIH HHS P50 CA186784
Abstract
Despite effective strategies, resistance in HER2
Indexed as
Drug Resistance, NeoplasmSignal TransductionAntineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibMechanistic Target of Rapamycin Complex 1Mevalonic AcidPhosphorylationTrastuzumabAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibMechanistic Target of Rapamycin Complex 1Mevalonic AcidTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.